Genomics startup 54Gene has commenced the winding down of its operations, marking a dramatic reversal after securing a total of $45 million in funding across three rounds. This decision, initially reported by TechCabal and confirmed by sources, saw the company begin its shutdown process in July 2023, with its website disappearing by September 2023 and its former PR agency disassociating itself from the venture.

Founded in 2019 by Dr. Abasi Ene-Obong, 54Gene was established with the ambitious mission to provide crucial genomic data on Africans. Its goal was to significantly bolster drug discovery efforts by global pharmaceutical companies, addressing a stark disparity where less than 3% of genetic material used in global pharmaceutical research originated from Africa. The company aimed to bridge this substantial gap in the global genomics market.

However, within just four years of its inception, 54Gene encountered significant turmoil, including a rapid succession of three CEO changes within a single year. Ron Chiarello, who assumed the CEO role in March 2023, publicly confirmed the financial challenges that necessitated the company's decision to initiate shutdown proceedings before his departure in July. He stated, "Unfortunately, the company could not continue to operate financially, and it began to wind down in July," providing the first official acknowledgment of 54Gene's closure.

As part of its winding-down efforts, 54Gene is actively seeking buyers for its assets, which include a valuable biobank containing invaluable biological samples critical for research. While company insiders consider these assets highly valuable, the sale process has been complicated by unresolved legal issues and outstanding debts to creditors, making the progress uncertain.

Further compounding the company's woes, Teresia Bost, 54Gene's former legal counsel and interim CEO, filed a lawsuit against the company. Her suit alleged "discriminatory behavior and creating a hostile work environment" during her tenure. Bost's appointment followed the dramatic exit of founder Dr. Abasi Ene-Obong in October 2022. Ene-Obong's departure occurred despite the company's substantial revenue from its COVID-19 testing facilities and a significant $25 million funding round just a year prior. He described his stepping down as a "difficult decision," indicating the company was undergoing a pivotal transition that would be better served by new leadership, having invested his life in building the company for four years.

Despite initial excitement surrounding Teresia Bost's appointment in 2021, when 54Gene lauded her as a "well-rounded executive with a depth of experience in the global pharmaceutical and biotech industry," she abdicated the position only five months later. According to Law360, a legal trade publication, Bost alleged that Tobi Oke, one of the company's investors, would "scream at her on video and phone meetings, degrading and humiliating her, and falsely criticized both her work product and legal work." Tobi Oke declined to comment on these allegations. Bost is pursuing legal action against five company associates in a New Jersey court in the U.S.

Commenting on the broader context of the shutdown, Ron Chiarello remarked, "When companies fail, no matter how altruistic their purpose, disagreements arise. It's my hope that when the dust settles, the idea behind 54gene continues in some way for the health benefit of Nigerians, all Africans, and people globally."

The abrupt collapse of 54Gene, a prominent player that had attracted significant funding, has raised concerns among industry observers about the repercussions on the broader genomics and health tech sector. There is apprehension that this downfall could deter global investors from supporting similar ventures, thereby creating uncertainty in a sector that was once perceived as highly promising. 54Gene's story stands as a cautionary tale, underscoring the inherent challenges and complexities of operating in capital-intensive industries like genomics, and highlighting the critical importance of financial prudence and strategic management amidst rapid growth and evolving business dynamics. Interestingly, Abasi Ene-Obong, the erstwhile co-founder and former CEO of 54Gene, has since launched another genomics company named Syndicate Bio.